tbuckley/cabot-search huggingface dataset:
Impact of a student pharmacist-directed pilot intervention on influenza vaccination documentation and administration rates in older adults receiving parenteral anticancer therapy.
Authors: E. Bridget Kim, Mark Zangardi, Leila Rostamnjad, Ryan David Nipp, Mimi Bartholomay, Laura White, Gayle C. Blouin
Journal: Journal of Clinical Oncology (2019)

71 Background: Annual influenza vaccination is recommended for individuals 6 months and older. Older adults are at high-risk of developing influenza and complications associated with the virus. However, &lt; 50% of patients with cancer receive the influenza vaccine annually. In previous work at our institution, a quality improvement project identified that only 40% of adult patients initiating parenteral anticancer therapy between September and December 2017 were documented to have received the influenza vaccine. Therefore, a multidisciplinary student pharmacist-directed pilot intervention was developed to improve influenza vaccine documentation and administration rates, and we sought to investigate the impact of this intervention. Methods: All adult patients (≥65 years old) scheduled for parenteral anticancer therapy during November 2018 were screened for influenza vaccination documentation. Patients were identified by reviewing infusion center schedule. Under supervision of board-certified oncology pharmacists, two student pharmacists evaluated influenza vaccination documentation in the institution/network electronic medical record (EMR) and outside records. Patients with unknown vaccination history were identified for interview by pharmacy students. The student pharmacists collaborated with oncology nurses and clinicians to order and administer influenza vaccine to patients who agreed to vaccination. Influenza vaccination status was updated in the EMR following record reviews/interviews. Results: Student pharmacists screened 617 patient EMRs and interviewed 124 patients to verify vaccination status. Furthermore, 33 patients received influenza vaccination as a direct result of student pharmacist intervention. Overall, rate of influenza vaccination status documentation was 60.5%. Conclusions: Compared with historic data, we found promising results for a student pharmacist-directed pilot intervention, which demonstrated the potential to improve influenza vaccination status documentation and administration among older adults receiving parenteral anticancer therapy.
Abstract 19734: Gdf-5 Deficiency Prevents Cardiac Rupture Following Acute Myocardial Infarction in Mice
Authors: Colin G White-Dzuro, Eric Shikatani, Abdul Momen, Mansoor Husain
Journal: Circulation (2016)

Background: Despite considerable advances in the treatment of myocardial infarction (MI), cardiac rupture remains a devastating complication. We previously showed that growth and differentiation fa...
Low and Very Low Bone Mineral Density Among Adult Survivors of Childhood Cancer Can be Predicted
Authors: Jenneke E. Van Atteveld, Saskia M.F. Pluijm, Kirsten K. Ness, Melissa M. Hudson, Wassim Chemaitilly, Sue C. Kaste, Leslie L. Robison, Sebastian J.C.M.M. Neggers, Marry M Van den Heuvel-Eibrink, Carmen L. Wilson
Journal: Blood (2018)
Abstract 653: The Long Noncoding RNA Landscape of the High Altitude Induced Thromboembolic Disorder: Role of Endogenous miRNA Sponge
Authors: Prabhash K Jha, Aatira Vijay, Amit Prabhakar, Tathagat Chatterjee, Nitin Bajaj, Velu Nair, Bhuvnesh Kumar, Mohammad Z Ashraf, Manish Sharma
Journal: Circulation Research (2019)

Background: The pathophysiology of Deep vein thrombosis (DVT) is considered as multifactorial, where thrombus formation is interplay of genetic and acquired risk factors. Lately, different pipelines have been developed to identify novel lncRNAs in different diseases, however a little is known about the expression profile and roles of lncRNAs in human subjects developing DVT at high altitude. Methods: In the present study, using RNA sequencing, we compared peripheral blood lncRNA expression profile in human High Altitude deep Vein Thrombosis (HA-DVT) patients with high altitude control and sea level control human subjects. We used DESeq to identify differentially expressed (DE) genes. We identified the noncoding RNAs by annotation database that includes lncRNAs from the NONCODE 3.0 human noncoding RNA database. This was followed by the functional characterization of the identified DE lncRNAs by Co-expressed protein-coding genes analysis. We further performed in silico putative lncRNA-miRNA association study to unravel the endogenous miRNA sponge associated with our candidate lncRNAs. Finally, to validate the in silico findings, siRNA knockdown assay of the candidate LncRNAs was conducted in primary endothelial cells Results: We identified 973 differentially expressed lncRNAs. Co-expressed protein-coding genes analysis resulted in a list of 722 coexpressed protein-coding genes with a Pearson correlation coefficients &gt;0.7. The functional annotation of co-expressed genes and putative proteins revealed their involvement in the hypoxia, immune response and coagulation cascade. Putative lncRNA-miRNA association analysis revealed several miRNAs associated with cardiovascular disorders. Through its miRNA response elements (MREs) to compete for miR-143 and miR-15, lncRNA-LINC00659 and UXT-AS1 regulates the expression of prothrombotic genes. Furthermore, in vitro RNA interference (siRNA) simultaneously suppressed lncRNAs and target gene mRNA level. Conclusions: This transcriptome profile describes several potential mechanisms of interaction between lncRNAs, the coding genes, miRNAs and regulatory transcription factors that define the thrombotic signature and may be used in establishing lncRNAs as biomarker in HA-DVT.
Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia
Authors: Claudia Lucia Sossa, Angela María Peña, Luis Antonio Salazar, Claudia Marcela Chalela, Juan Jose Rey, Manuel Rosales, Maria Luna-Gonzalez, Sergio Serrano, Jose Sandoval-Sus, Pau Montesinos, Maria Fernanda Ortiz, Javier Oliver Delgadillo, Sandra Vanesa Rios, Sara Ines Jimenez
Journal: Blood (2018)
Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia.
Authors: Bijan Moshaver, Angele Kelder, Guus Westra, Anna van Rhenen, Gert J. Ossenkoppele, Sonja Zweegman, Gerrit J. Schuurhuis
Journal: Blood (2007)
A Pilot Data Analysis of a Metabolomic Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) Based Study of Patients with Sickle Cell/Beta Thalassemia
Authors: Ioannis Papassotiriou, Christos Poziopoulos, Georgia Avgerinou, Claudia R. Morris, Ersi Voskaridou
Journal: Blood (2018)
BEACON trial in colorectal cancer is “single worst reported,” says critic
Authors: Jacqui Wise
Journal: BMJ (2019)

A study of a chemotherapy-free targeted regimen for colorectal cancer published recently in the New England Journal of Medicine has been denounced as the “single worst reported randomised controlled trial.”

Vinay Prasad, a practising haematologist-oncologist and associate professor of medicine at Oregon Health and Science University in Portland, Oregon, harshly criticised the BEACON study on Twitter and in the podcast Plenary Session for failing to provide basic information and for numerous redactions in the original published protocol.1

The open label phase III trial in patients who had metastatic colorectal cancer with the BRAF V600E mutation was presented during an oral session at the 2019 European Society for Medical Oncology conference at the end of September and was simultaneously published online in the New England Journal of Medicine ,2 although at the time of publication some parts of the study protocol were redacted.

In the trial 665 patients were assigned to triple therapy …
Increased Th17/Treg Ratio In Liver Chronic Graft-Versus-Host-Disease
Authors: Florent Malard, Céline Bossard, Eolia Brissot, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, jean François Mosnier, Philippe Moreau, Marc Gregoire, Béatrice Gaugler, Mohamad Mohty
Journal: Blood (2013)
MicroRNA delivery through nanoparticles
Authors: Sharon Wei Ling Lee, Camilla Paoletti, Marco Campisi, Tatsuya Osaki, Giulia Adriani, Roger D. Kamm, Clara Mattu, Valeria Chiono
Journal: Journal of Controlled Release (2019)

MicroRNAs (miRNAs) are attracting a growing interest in the scientific community due to their central role in the etiology of major diseases. On the other hand, nanoparticle carriers offer unprecedented opportunities for cell specific controlled delivery of miRNAs for therapeutic purposes. This review critically discusses the use of nanoparticles for the delivery of miRNA-based therapeutics in the treatment of cancer and neurodegenerative disorders and for tissue regeneration. A fresh perspective is presented on the design and characterization of nanocarriers to accelerate translation from basic research to clinical application of miRNA-nanoparticles. Main challenges in the engineering of miRNA-loaded nanoparticles are discussed, and key application examples are highlighted to underline their therapeutic potential for effective and personalized medicine.
High-Dose Intravenous Immunoglobulin and Immunosuppressive Therapy Have Therapeutic Potential for Non-Infectious Myelopathy and Peripheral Neuropathy Following Cord Blood Transplantation
Authors: Michiho Ebihara, Shinsuke Takagi, Yoshikazu Uesaka, Takashi Mitsuki, Mitsuhiro Yuasa, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Yukako Koike, Shigeyoshi Makino, Akiko Yoneyama, Atsushi Wake, Naoyuki Uchida, Shuichi Taniguchi
Journal: Blood (2018)
Johnson &amp; Johnson recalls its Baby Powder after FDA finds asbestos in sample
Authors: Owen Dyer
Journal: BMJ (2019)

Johnson & Johnson, which for decades has insisted that its Baby Powder contains zero asbestos, has recalled one lot of the product—about 33 000 bottles—after the US Food and Drug Administration found asbestos in a sample bought online.

The company said that it was acting from “an abundance of caution” in withdrawing the lot numbered 22318RB, although the FDA advised consumers who had bought Baby Powder from that lot to “stop using it immediately.”

The FDA said that it had tested bottles from two different lots and found chrysotile asbestos—the type most associated with adverse health effects—in one of them. The agency has a long running programme of buying consumer products itself and testing them. …
Lenalidomide and Rituximab Combined with CEP Chemotherapy (R2CEP) for Patients with Relapsed or Refractory B-Cell Lymphoma
Authors: Stephanie Guidez, Cécile Gruchet, Paul Franques, Claire Darras, Arthur Bobin, Cecile Tomowiak, Antoine Machet, Isabelle Princet, Xavier Leleu, Vincent Delwail
Journal: Blood (2018)
Transcriptional Atlas of Intestinal Immune Cells Reveals that Neuropeptide α-CGRP Modulates Group 2 Innate Lymphoid Cell Responses
Authors: Heping Xu, Jiarui Ding, Caroline B.M. Porter, Antonia Wallrapp, Marcin Tabaka, Sai Ma, Shujie Fu, Xuanxuan Guo, Samantha J. Riesenfeld, Chienwen Su, Danielle Dionne, Lan T. Nguyen, Ariel Lefkovith, Orr Ashenberg, Patrick R. Burkett, Hai Ning Shi, Orit Rozenblatt-Rosen, Daniel B. Graham, Vijay K. Kuchroo, Aviv Regev, Ramnik J. Xavier
Journal: Immunity (2019)
Lung Parenchyma–Derived IL-6 Induces Alloantigen Specific Th17 Differentiation Within The Lung and Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation
Authors: Antiopi Varelias, Kate H Gartlan, Stuart D Olver, Katie E Lineburg, Rachel D Kuns, Mary Lor, Bianca E Teal, Melody Cheong, Motoko Koyama, Kate A Markey, Kylie Alexander, Alison Budelsky, Elise Sturgeon, Justine Leach, Judy Avery, Glen A Kennedy, Siok- Tey, Andrew D Clouston, Kelli PA MacDonald, Geoff R Hill
Journal: Blood (2013)
Fully Automated Washing of Cryopreserved Peripheral Blood Stem Cells (PBSC): Results of a Prospective, Multicenter, Clinical Trial.
Authors: Riccardo Saccardi, Miguel Blanquer, Margherita Boieri, Christoph Bucher, Christian Chabannon, Simone Dal Pozzo, Benjamin Esterni, Francesco Lanza, Claude Lemarie, Maria Dolores Lopez Lucas, Doris Loutan, Jose M Morelada Jimenez, Andre Tichelli, Boris Calmels
Journal: Blood (2012)
Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice
Authors: Lisa Munakata, Yoshihiko Tanimoto, Akio Osa, Jie Meng, Yasunari Haseda, Yujiro Naito, Hirotomo Machiyama, Atsushi Kumanogoh, Daiki Omata, Kazuo Maruyama, Yasuo Yoshioka, Yoshiaki Okada, Shohei Koyama, Ryo Suzuki, Taiki Aoshi
Journal: Journal of Controlled Release (2019)

Type-A CpG oligodeoxynucleotides (ODNs), which have a natural phosphodiester backbone, is one of the highest IFN-α inducer from plasmacytoid dendritic cells (pDC) via Toll-like receptor 9 (TLR9)-dependent signaling. However, the in vivo application of Type-A CpG has been limited because the rapid degradation in vivo results in relatively weak biological effect compared to other Type-B, -C, and -P CpG ODNs, which have nuclease-resistant phosphorothioate backbones. To overcome this limitation, we developed lipid nanoparticles formulation containing a Type-A CpG ODN, D35 (D35LNP). When tested in a mouse tumor model, intratumoral and intravenous D35LNP administration significantly suppressed tumor growth in a CD8 T cell-dependent manner, whereas original D35 showed no efficacy. Tumor suppression was associated with Th1-related gene induction and activation of CD8 T cells in the tumor. The combination of D35LNP and an anti-PD-1 antibody increased the therapeutic efficacy. Importantly, the therapeutic schedule and dose of intravenous D35LNP did not induce apparent liver toxicity. These results suggested that D35LNP is a safe and effective immunostimulatory drug formulation for cancer immunotherapy.
Durable Chimerism, Absence of Graft-Versus-Host Disease and the Induction of Donor Specific Tolerance in Recipients of HLA Disparate Living Donor Kidney Transplants and Therapeutic Cell Transfer
Authors: Joseph Leventhal, Michael Abecassis, Joshua Miller, Lorenzo Gallon, Kadiyala Ravindra, David J Tollerud, Bradley J King, Geoffrey Herzig, Roger Herzig, Suzanne T Ildstad
Journal: Blood (2011)
Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms’ Tumor Protein WT1: A Phase I/II Trial.
Authors: Zwi N. Berneman, Ann Van Driessche, Ann Van de Velde, Griet Nijs, Tessa Braeckman, Barbara Stein, Katrien Vermeulen, Katrien Pieters, Alain P. Gadisseur, Wilfried A. Schroyens, I. Jolanda de Vries, David A. Price, Viggo F. Van Tendeloo
Journal: Blood (2007)
Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA
Authors: Sudipto Mukherjee, Tomas Radivoyevitch, Brian P. Hobbs, Xuefei Jia, Rami S. Komrokji, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Jaroslaw P. Maciejewski, Aziz Nazha, Mikkael A. Sekeres
Journal: Blood (2018)
FcmR Shapes BCR Signaling in IgM-Positive Leukemia
Authors: Alexandra da Palma Guerreiro, Cornelia Dorweiler, Ismini Halmer, Olaf Merkel, Elena Maria Hartmann, Valeska Berg, Nina Reinart, Günter Fingerle-Rowson, Gero Knittel, Christian Pallasch, Andreas Rosenwald, Christian Reinhardt, Clemens-Martin Wendtner, Michael Hallek, Lukas P. Frenzel
Journal: Blood (2018)
Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)
Authors: Shaji K Kumar, Ann E Engebretson, Francis K Buadi, Martha Q Lacy, Angela Dispenzieri, Mei Sheng Duh, Sc.D Sc.D, Marie-Hélène Lafeuille, Patrick Lefebvre, Wendy Y Cheng, Katherine Dea, Mark Yap, Shanmugapriya Saravanan, Iwen Pan, Debra Rembert, Rahul Dhanda, Liviu Niculescu, Abbie Ba-Mancini, Esprit Ma, Maureen Quick, Ocn Ocn, S. Vincent Rajkumar
Journal: Blood (2013)
Abstract 755: Fas Ligand- and Nitric Oxide-Releasing Stent
Authors: Mehmet H Kural, Juan Wang, Liqiong Gui, Guangxin Li, Yifan Yuan, Katherine L Leiby, Elias Quijano, Geroge Tellides, W. Mark Saltzman, Laura E Niklason
Journal: Circulation Research (2019)

To restore blood flow in stenotic vessels such as coronary arteries, metallic vascular stents are often used. However, stent deployment under high pressure leads to vascular wall and smooth muscle (SMC) damage, with compensatory thrombosis, inflammation, and neointimal proliferation of SMCs. These events result in vessel re-occlusion and treatment failure. In an effort to prevent intimal hyperplasia and treatment failure, drug-eluting stents were developed roughly 15 years ago. These stents release global inhibitors of proliferation (eg. “mTOR inhibitors”) which stop the growth of SMC as well as vascular endothelial cells (EC). Despite being widely used, drug-eluting stents mandate long-term treatment with potent anticoagulants. This is because mTOR inhibitors prevent re-endothelialization of the stent surface, leaving the clot-inducing metal exposed to the bloodstream. Yet, long-term dual antiplatelet therapy leads to increased risk of bleeding/stroke and myocardial infarction. Here, we leveraged the fact that nitric oxide (NO) increases Fas receptors on the SMC surface. Fas forms a death-inducing complex upon binding to Fas ligand (FasL), while ECs are relatively resistant to this pathway (Figure 1). Selected doses of FasL and NO donor synergistically increased SMC apoptosis and inhibited SMC growth more potently than did everolimus or sirolimus, while having no significant effect on EC viability and proliferation. We verified this differential effect in an ex vivo pig coronary artery model, where the intimal thickening was inhibited by the drug combination, but endothelial viability was retained. We also deployed FasL and NO donor-releasing ethylene-vinyl acetate copolymer (EVAc)-coated stents into pig coronary arteries, and cultured them in perfusion bioreactors for one week. FasL and NO donor, released from the stent coating, killed SMCs in the proximity of the stent struts, even in the presence of flow rates mimicking those of native arteries. Therefore, the FasL-NO donor-combination has the potential to prevent intimal hyperplasia and in-stent restenosis, without harming endothelial restoration, and hence may be a superior drug delivery strategy for drug-eluting stents.
GSDMD membrane pore is critical for IL-1β release and antagonizing IL-1β by hepatocyte-specific nanobiologics is a promising therapeutics for murine alcoholic steatohepatitis
Authors: Jingyun Luan, Wei Chen, Jiajun Fan, Shaofei Wang, Xuyao Zhang, Wenjing Zai, Xin Jin, Yichen Wang, Zhenyi Feng, Jinghui Zhang, Ming-Lin Liu, Dianwen Ju
Journal: Biomaterials (2019)
Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)
Authors: Jorge E. Cortes, Meir Wetzler, Jeffrey H. Lipton, H. Jean Khoury, Patricia Kropf, Mauricette Michallet, Michele Baccarani, Delphine Rea, Charles Chuah, Raghunadharao Digumarti, Purvish M. Parikh, Elizabeth Li, Mihaela C. Munteanu, Peter D. Brown, Franck E. Nicolini
Journal: Blood (2013)
Racial disparities in utilization of gene expression testing in breast cancer patients at an academic medical center.
Authors: Laura Alder, Harry Douglas Bear, Mary Helen Hackney
Journal: Journal of Clinical Oncology (2019)

142 Background: Gene expression profiling of breast cancers, such as the OncotypeDx (ODX) test, PAM 50 and Mammaprint, can define the risk of distant recurrence and assist with decisions about adjuvant chemotherapy. A recent study of all breast cancer patients in Virginia found that only 11.7 % of Caucasian Americans (CA) and 5.1% of African Americans (AA) received genomic testing. Methods: We utilized the Virginia Commonwealth University Health System (VCUHS) Tumor Registry and billing data from 2010-2017 to identify all patients that met the following criteria per NCCN guidelines for genomic testing: early stage (stage I or II) breast cancer, estrogen and/or progesterone receptor positive and lymph node-negative breast cancer. We also obtained records from Genomic Health on ODX testing ordered through VCU Health. Additionally, ODX utilization was stratified by race. We then performed Chi Square analysis. Results: 1080 patients were eligible per NCCN Guidelines. Of these, 248 were eliminated due to having only radiation performed at VCU. 39 were eliminated because initial treatments were at outside hospitals. Of the remaining 793, 536 were CA, 232 AA, 9 Asian and 16 other. Among the patients for whom a genomic test was appropriate, the proportion who actually had such a test performed were: 83.4% for CA, 71.98% for AA, 55.56% for Asians, 81.25 % for Others and 79.7% overall. There was a significant difference between utilization in CAs and AAs (p &lt; 0.001). Conclusions: Breast cancer patients at VCU Health are far more likely to receive gene expression profiling overall compared to the Commonwealth of VA as a whole. This may reflect more equitable and guideline-compliant care in an academic/safety net health system.
Prevalence and Risk Factors of Low Bone Mineral Density and Fractures of Young Thalassemia Patients
Authors: Pokpong Piriyakhuntorn, Adisak Tantiworawit, Mattabhorn Phimphilai, Somdet Srichairatanakool, Waralee Teeyasoontranon, Thanawat Rattanathammethee, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada, Pimlak Charoenkwan
Journal: Blood (2018)
Abstract 633: Semaphorin3e-Plexind1 Signaling is Required for Cardiac Ventricular Compaction
Authors: Reddemma Sandireddy, Dasan M Cibi, Anamika Singh, Nicole Tee, Akiyoshi Uemura, Jonathan A Epstein, Manvendra K Singh
Journal: Circulation Research (2019)

Left ventricular noncompaction (LVNC) is one of the most common forms of genetic cardiomyopathy characterized by excessive trabeculation and impaired myocardial compaction during fetal development. LVNC patients are at higher risk to develop left or right ventricular failure, or both. While key regulators for cardiac chamber development are well studied, the role of Semaphorin-Plexin signaling in this process remains poorly understood. Here, we demonstrate that genetic deletion of Plxnd1, a class 3 semaphorin receptor in endothelial cells, leads to severe cardiac chamber defects, as characterized by excessive trabeculation and non-compaction similar to LVNC patients. Loss of Plxnd1 results in decreased expression of extracellular matrix (ECM) proteolytic genes leading to excessive deposition of cardiac jelly. We demonstrate that Plxnd1 deficiency is associated with an increase in the expression of Notch and its downstream target genes. In addition, inhibition of Notch signaling pathway can partially rescue the excessive trabeculation and non-compaction phenotype present in Plxnd1 mutants. Furthermore, we demonstrate that Semaphorin 3e (Sema3e), one of Plxnd1’s ligands is expressed in the developing heart and is required for myocardial compaction. Collectively, our results demonstrate that the Sema3e-Plxnd1 pathway is essential for myocardial trabeculation and compaction.
Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)
Authors: Paolo Anderlini, Rima M Saliba, Celina Ledesma, Christina M Chancoco, Sandra Acholonu, Rosamar Valverde, Uday R Popat, Chitra M Hosing, Amin M Alousi, Elizabeth J Shpall, Yago Nieto, Stefan O Ciurea, Issa Khouri, Richard Champlin
Journal: Blood (2011)
Serum Free Light Chain Ratio (FLCr) Is a Powerful Prognostic Factor For Survival In Newly Diagnosed Multiple Myeloma (MM) Eligible For High Dose Melphalan (HDM)
Authors: Graça Esteves, Manuel L Neves, Helena Martins, Carlos M. Martins, Maria Joao Costa, Sara Valle, Conceição Lopes, João Raposo, Lurdes Guerra, Blanca Polo, Ana Alho, Carolina Viveiros, Susana Mendes, Rita Ferreira, Eduardo Espada, Inês Conde, Daniela Alves, Joao F Lacerda, Helena Proença, José A Carmo
Journal: Blood (2013)